These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27581642)

  • 61. Design, Synthesis, and in vitro Biological Evaluation of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors.
    Li X; Zhang J; Zhao L; Yang Y; Zhang H; Zhou J
    ChemMedChem; 2018 Jul; 13(13):1363-1368. PubMed ID: 29808961
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure.
    Qi J
    Cold Spring Harb Perspect Biol; 2014 Dec; 6(12):a018663. PubMed ID: 25452384
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bromodomain Drug Discovery - the Past, the Present, and the Future.
    Pervaiz M; Mishra P; Günther S
    Chem Rec; 2018 Dec; 18(12):1808-1817. PubMed ID: 30289209
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Methylpyrrole inhibitors of BET bromodomains.
    Hasvold LA; Sheppard GS; Wang L; Fidanze SD; Liu D; Pratt JK; Mantei RA; Wada CK; Hubbard R; Shen Y; Lin X; Huang X; Warder SE; Wilcox D; Li L; Buchanan FG; Smithee L; Albert DH; Magoc TJ; Park CH; Petros AM; Panchal SC; Sun C; Kovar P; Soni NB; Elmore SW; Kati WM; McDaniel KF
    Bioorg Med Chem Lett; 2017 May; 27(10):2225-2233. PubMed ID: 28268136
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
    Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y
    J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer.
    Hong SH; Eun JW; Choi SK; Shen Q; Choi WS; Han JW; Nam SW; You JS
    Oncotarget; 2016 May; 7(22):32628-40. PubMed ID: 27081696
    [TBL] [Abstract][Full Text] [Related]  

  • 67. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.
    Morse MA; Balogh KK; Brendle SA; Campbell CA; Chen MX; Furze RC; Harada IL; Holyer ID; Kumar U; Lee K; Prinjha RK; Rüdiger M; Seal JT; Taylor S; Witherington J; Christensen ND
    Antiviral Res; 2018 Jun; 154():158-165. PubMed ID: 29653131
    [TBL] [Abstract][Full Text] [Related]  

  • 68. An array of bengamide E analogues modified at the terminal olefinic position: synthesis and antitumor properties.
    Martín-Gálvez F; García-Ruiz C; Sánchez-Ruiz A; Valeriote FA; Sarabia F
    ChemMedChem; 2013 May; 8(5):819-31. PubMed ID: 23512621
    [TBL] [Abstract][Full Text] [Related]  

  • 69. What structural modifications can be used for BRD4 inhibitors for their use in leukemia therapy?
    Yao D; Liu J; Ouyang L
    Future Med Chem; 2017 Jun; 9(9):839-842. PubMed ID: 28635318
    [No Abstract]   [Full Text] [Related]  

  • 70. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
    Hölscher AS; Schulz WA; Pinkerneil M; Niegisch G; Hoffmann MJ
    Clin Epigenetics; 2018; 10():1. PubMed ID: 29312470
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Stereoselective synthesis of allele-specific BET inhibitors.
    Bond AG; Testa A; Ciulli A
    Org Biomol Chem; 2020 Oct; 18(38):7533-7539. PubMed ID: 32756710
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds.
    Chan KH; Zengerle M; Testa A; Ciulli A
    J Med Chem; 2018 Jan; 61(2):504-513. PubMed ID: 28595007
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A novel 7-phenoxy-benzimidazole derivative as a potent and orally available BRD4 inhibitor for the treatment of melanoma.
    Horai Y; Suda N; Uchihashi S; Katakuse M; Shigeno T; Hirano T; Takahara J; Fujita T; Mukoyama Y; Haga Y
    Bioorg Med Chem; 2024 Oct; 112():117882. PubMed ID: 39167978
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Disrupting Acetyl-lysine Interactions: Recent Advance in the Development of BET Inhibitors.
    Zhang F; Ma S
    Curr Drug Targets; 2018; 19(10):1148-1165. PubMed ID: 29189147
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Novel phenanthridin-6(5H)-one derivatives as potent and selective BET bromodomain inhibitors: Rational design, synthesis and biological evaluation.
    Zhi Y; Wang S; Huang W; Zeng S; Liang M; Zhang C; Ma Z; Wang Z; Zhang Z; Shen Z
    Eur J Med Chem; 2019 Oct; 179():502-514. PubMed ID: 31276895
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Exploiting the 7-methylimidazo[1,5-a]pyrazin-8(7H)-one scaffold for the development of novel chemical inhibitors for Bromodomain and Extraterminal Domain (BET) family.
    Yang Y; Chen P; Zhao L; Zhang F; Zhang B; Xu C; Zhang H; Zhou J
    Bioorg Chem; 2019 Sep; 90():103044. PubMed ID: 31220668
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Click Chemistry: Novel Applications in Cell Biology and Drug Discovery.
    Gehringer M; Laufer SA
    Angew Chem Int Ed Engl; 2017 Dec; 56(49):15504-15505. PubMed ID: 29068506
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The design, synthesis and cellular imaging of a tumor-anchored, potent and cell-permeable BRD4-targeted fluorescent ligands.
    Zhang H; Zhang M; Zheng YC; Zhang JG; Xu H
    Bioorg Chem; 2021 Sep; 114():105120. PubMed ID: 34216895
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evaluation of linker length effects on a BET bromodomain probe.
    Traquete R; Henderson E; Picaud S; Cal PMSD; Sieglitz F; Rodrigues T; Oliveira R; Filippakopoulos P; Bernardes GJL
    Chem Commun (Camb); 2019 Aug; 55(68):10128-10131. PubMed ID: 31386708
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery.
    Liang D; Yu Y; Ma Z
    Eur J Med Chem; 2020 Aug; 200():112426. PubMed ID: 32502863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.